10 AI News Investors Probably Missed

8. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Number of Hedge Fund Holders: 16

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotech company leveraging AI and technology to advance drug discovery. It also recently announced its LOWE Drug Discovery Software, a language model designed to streamline drug discovery by running experiments with AI on large datasets.

Recursion (NASDAQ:RXRX) reported early data from its AI-designed CDK7 inhibitor, REC-617, in a Phase 1/2 trial for advanced solid tumors. Created through AI-led precision methods, REC-617 reached clinical testing within 12 months of candidate identification. It demonstrated promising pharmacokinetics and pharmacodynamics, with rapid absorption, controlled target engagement, and favorable safety. The study observed one partial response in a heavily pre-treated patient and stable disease in others. These findings highlight REC-617’s potential for addressing resistance mechanisms in cancer therapy. Recursion plans further dose escalation and combination trials in 2025, emphasizing its AI-driven approach to drug development.